91 results about "Galectin" patented technology

The invention belongs to the field of chemical medicines, and particularly relates to a combined medicine for preventing and / or treating prostatic cancer, application of the combined medicine and a medicine composition. The combined medicine disclosed by the invention comprises immune cells with enhanced infiltration degree and a galectin-1 inhibitor; the immune cells with enhanced infiltration degree are natural killer (NK) cells with TTTY15-USP9Y chimera RNA knocked out, the infiltration degree and anti-tumor activity of the NK cells in a prostate cancer microenvironment can be improved, and the activated NK cells have a stronger killing effect on tumor cells in vitro. The immune cells with enhanced infiltration degree and the galectin-1 inhibitor are combined for use, so that the composition shows a synergistic effect in treatment of prostatic cancer, and has a wide application prospect.

The present invention relates to a D-galactopyranose compound of formula (1)whereinthe pyranose ring is α-D-galactopyranose, and these compounds are high affinity galectin-1 and / or galectin 3 inhibitors for use in treatment of inflammation; fibrosis; scarring; keloid formation; aberrant scar formation; surgical adhesions; septic shock; cancer; metastasising cancers; autoimmune diseases, metabolic disorders; heart disease; heart failure; pathological angiogenesis; eye diseases; atherosclerosis; metabolic diseases; diabetes type I; diabetes type II; insulin resistance; Diastolic heart failure; asthma; liver disorders.

Disclosed herein are anti-Galectin-9 antibodies and methods of using in modulating (e.g., increasing) immune responses in a subject, either taken alone or in combination with an immune checkpoint inhibitor, such as a PD-1 inhibitor.

The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.

The invention discloses a compound of a Galectin-3 and EGFR (Epidermal Growth Factor Receptor) double-target inhibitor in the technical field of biological medicines, and the compound disclosed by the invention not only shows a relatively strong Galectin-3 and EGFR binding effect, but also has certain in-vitro anti-hepatic fibrosis activity, and can be applied to Galectin-3 and EGFR target related tumor diseases. As a double-target anti-hepatic fibrosis candidate compound based on Galectin-3 and EGFR, which is reported for the first time, the compound has further values of research and development and research of original new drugs based on double targets of Galectin-3 and EGFR.

The present invention relates to a compound of formula (I) for use in a method for treatment of a cancer having a higher expression of galectin-1 compared to normal tissue.

The present invention relates to compounds of Formula (I)wherein Ar1, R1, R2a, R2b, and R3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

The present invention relates to a composition for preventing or treating lupus or glomerulonephritis comprising a recombinant stabilized Galectin-9 protein. Specifically, the recombinant stabilized Galectin-9 protein of the present invention has been confirmed to exhibit safety in a systemic lupus erythematosus (SLE) animal model, reduce skin lesions, lymphadenopathy, and proteinuria caused by lupus, ameliorate lupus nephritis and glomerulonephritis, and decrease the concentration of anti-dsDNA antibodies in plasma. Accordingly, the recombinant stabilized Galectin-9 protein of the present invention can be effectively used as an active ingredient in a composition for preventing or treating lupus or glomerulonephritis.

The invention discloses a galectin MsGal-3 and an application of the galectin MsGal-3 in resisting MSRV infection in micropterus salmoides. Galectin MsGal-3 (the accession number is PV454561) is obtained through screening and identification from a liver transcriptome of micropterus salmoides, a target gene is synthesized, plasmids are constructed, then an escherichia coli E.coli expression strain BL21 is adopted for induced expression, and MsGal-3 protein is obtained through purification and can be used for preventing and treating micropterus salmoides rhabdovirus infection.

The present invention provides methods for determining whether a subject suspected of having a myocardial infarction is suffering from type I or type II myocardial infarction. In particular, systems and methods are provided that employ a probability score based on a decision tree-based algorithm to process the subject's gender, age, and cardiac troponin concentration, as well as the subject's galectin-3 (Gal-3) concentration.

The present invention relates to a recombinant stabilized galectin 9 protein and the use thereof, and more specifically, relates to a pharmaceutical composition comprising the recombinant stabilized galectin 9 protein for prevention or treatment of rheumatoid arthritis and a bone disease. The recombinant stabilized galectin 9 protein differs from the wild-type galectin 9 protein in that the amino acids in the link region connecting two carbohydrates recognition domains (CRDs) are deleted, and the amino acids in the C-terminal CRD (CCRD) are deleted and substituted.

Provided herein are affinity matured anti-galectin-9 (Gal9) antibodies. The antibodies have improved binding affinity to Gal9. Also provided herein are method of use of the affinity matured anti-Gal9 antibodies, including methods of treatment of cancer, methods of rescuing or promoting effector T cell proliferation, methods of enhancing effector T cell activity, and / or of identifying and treating cancer in a subject including the administration of the anti-Gal9 antibodies described herein. Also provided are polynucleotides encoding the heavy chain or the light chain or the antigen-binding portion thereof described herein, and vectors, especially expression vectors, including the polynucleotides described herein.

The present invention provides methods for determining whether a subject suspected of having myocardial infarction is experiencing type I myocardial infarction or type II myocardial infarction. In particular, systems and methods are provided for processing the gender, age, and cardiac troponin concentration of a subject, as well as the galectin-3 (Gal-3) concentration of a subject, employing probability scoring based on a decision tree algorithm.

The present invention relates to a high affinity galectin-3 inhibitor alpha-D-galactopyranose derivative of formula (I), a pharmaceutical salt or solvate thereof, for use in treatment of inflammation.

The present application belongs to the field of chemical medicine, and particularly relates to a combined drug for preventing and / or treating prostate cancer, use and pharmaceutical composition thereof. The combined drug of the present application is an immune cell with enhanced infiltration degree and a galectin-1 inhibitor; the immune cell with enhanced infiltration degree is a natural killer (NK) cell with TTTY15-USP9Y chimera RNA knocked out, which can increase the infiltration degree and anti-tumor activity of the NK cell in the prostate cancer microenvironment, and the activated NK cell has stronger killing effect on tumor cells in vitro. The present application combines the immune cell with enhanced infiltration degree and the galectin-1 inhibitor, and the combination shows synergistic effect in treating prostate cancer, and has wide application prospect.

To provide an osteoclast fusion inhibitor that is highly effective and has few side effects. [Solution] An osteoclast fusion inhibitor containing an anti-galectin-3 neutralizing antibody as an active ingredient.

A method for treating diastolic heart failure (heart failure with preserved ejection fraction (HFpEF)) in a subject in need thereof is provided including administering a therapeutically effective amount of a galectin-3 inhibitor to the subject.

According to the application of a reagent for detecting the biomarker in preparation of a xerophthalmia diagnosis and typing detection reagent, the galectin-9 plays an important role in the occurrence and development process of the xerophthalmia, the expression level of the galectin-9 has a certain correlation with the severity of the xerophthalmia, and the galectin-9 is expected to be used as the biomarker for diagnosis and treatment of the xerophthalmia and can be used for preparing the xerophthalmia diagnosis and typing detection reagent. By detecting the expression condition of Galectin-9 in tears, early and accurate diagnosis of the dry eye and quantitative evaluation of the disease degree are achieved, in addition, Galectin-9 expressed on T cells plays an important role in immune inflammation of the dry eye, ocular surface damage of the dry eye can be relieved by locally intervening Galectin-9 through conjunctiva, and Galectin-9 serves as a novel potential target and has a good application prospect. A new way is opened up for diagnosis and treatment of xerophthalmia, a therapeutic drug or an intervention means developed for Galectin-9 can regulate immune response, inhibit inflammatory response, improve tear secretion and the like from the etiological level, and an existing xerophthalmia treatment mode is expected to be changed, so that the treatment effect is improved, the prognosis of a patient is improved, and the clinical application prospect is broad. The application prospect in the field of diagnosis and treatment of the xerophthalmia is wide, and a certain significance is achieved for improving the overall prevention and treatment level of the xerophthalmia.

The present invention belongs to the field of biopharmaceutical technology, and specifically discloses a TIM-3 affinity peptide and its application. The present invention obtains TIM-3 protein affinity peptide TBS-22 (as shown in SEQ ID NO.1) by screening through phage display seven peptide library high-throughput screening technology, and obtains mutant peptide TBSM-3 (isoleucine at position 6 is mutated to histidine, as shown in SEQ ID NO.2) through later optimization and transformation. The present invention shows through in vitro cell level experiments and mouse tumor-bearing experiments that TIM-3 affinity peptide can affinity TIM-3 protein, block the interaction between TIM-3 and its ligand Galectin-9, thereby exerting anti-tumor efficacy, can be used to prepare anti-tumor drugs, has good medical application prospects, and provides a new option for tumor immunotherapy.

The application discloses application of citrullinated galectin-1 polypeptide in preparation of a rheumatoid arthritis diagnosis product, and belongs to the technical field of rheumatoid arthritis diagnosis. The amino acid sequence of the citrullinated galectin-1 polypeptide is GD-Cit-WSSQQGSKAVYPE; the product is used for detecting the content of anti-citrullinated galectin-1 polypeptide antibody in a biological sample of a patient, and the antibody level is significantly different between RA patients, normal healthy people and other common rheumatic immune disease patients who are easily confused with rheumatoid arthritis. The product has good sensitivity to common RA, RA with normal ESR and CRP, and anti-CCP antibody / RF negative RA patients, and has good supplementary diagnosis value for the diagnosis of RA.

Provided herein are methods and compositions for suppressing a foreign body reaction, such as an implant-associated inflammation in a subject, by using an anti-Galectin-3 antibody. Such methods and compositions can be used in various areas applications where an implant is introduced, such as in brain-computer interface (BCI).

The present invention relates to a stabilized pharmaceutical formulation comprising a recombinant stabilized galectin-9 protein. More specifically, the invention provides a pharmaceutical formulation with improved stability through the combination of a buffer and a stabilizer.

The present disclosure provides a composition comprising a compound of Formula I, or pharmaceutically acceptable salt thereof, and / or a compound of Formula II, or pharmaceutically acceptable salt thereof, for use in inhibiting Galectin-3. The composition may be for use in the treatment and / or prevention of a disease, disorder, state or condition wherein inhibiting Galectin-3 would be beneficial for the treatment and / or prevention of the disease, disorder, state or condition. The disease, disorder, state or condition may be cancer, cancer metastasis, fibrosis, inflammation, diabetes and / or one or more other disease, disorder, state or condition affected and / or mediated by Galectin-3.

The invention provides humanized monoclonal antibodies against Gal9, and method of using the antibodies to treat cancer, including combination therapy with antagonists of the PD-1 / PD-L1 immune checkpoint.

This invention provides novel human antibodies that bind to human galectin-9, and their therapeutic use in the treatment of cancer. [Solution] Provided are isolated anti-galectin-9 antibodies that bind to epitopes in the glycan recognition domain (CRD) of galectin-9 polypeptides, and methods for using anti-galectin-9 antibodies to inhibit galectin-9-mediated signaling pathways or to eliminate diseased cells expressing galectin-9. Such anti-galectin-9 antibodies may also be used to diagnose and / or treat galectin-9-related diseases, such as autoimmune diseases and solid tumors.

The invention discloses an application of OTX008 in the treatment of HSV-1 virus infection. The application verifies that the galectin-1 selective inhibitor OTX008 can remarkably promote activation of an I-type interferon signal channel of a host after virus infection by constructing a mouse model infected by an HSV-1 virus; tissue inflammation damage caused by virus infection can be relieved; the immunopotentiator shows an immunopotentiation effect in mouse peritoneal macrophages. Therefore, the OTX008 disclosed by the invention can be used for promoting the function of an innate immune cell and inhibiting the replication of the HSV-1 virus in the cell; an immune escape strategy of the HSV-1 virus is cracked; the defect of high drug resistance of the traditional HSV-1 virus treatment drug is overcome to a certain extent; according to the application, a new host drug target spot is found, and a good clinical application prospect in resisting HSV-1 virus infection is shown.

Disclosed herein are combination therapies for treating hematological malignancies (e.g., acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)) using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17) and one or more chemotherapeutic agents, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.

Provided herein are antibodies that target Galectin-3. Such antibodies are used in methods of treating epilepsy and related neurological disorders, such as Alzheimer's disease (AD) and Parkinson's disease (PD).